Method of treating or preventing fibromyalgia and other somatoform disorders with a highly selective norepinephrine reuptake inhibitor
AssigneePharmacia & Upjohn Company
InventorsErik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
Life of this patent
Estimating the term…
Abstract
This application relates to methods for treating humans suffering from, fibromyalgia or other somatoform disorders where inhibiting reuptake of norepinephrine is a benefit. The methods comprise a compound having a pharmacological selectivity of serotonin (K1)/norepinephrine (K1) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.
Claims39
A method of treating an individual suffering from fibromyalgia and other somatoform disorders, the method comprising the step of administering to the individual a therapeutically effective amount of a composition comprising a compound having a pharmacological selectivity of serotonin (K1)/norepinephrine (K1) of at least about 5000.
A method of treating treating an individual suffering from fibromyalgia and other somatoform disorders while diminishing adverse side effects, the method comprising the step of administering to the individual a total dose of about 0.1 to about 10 mg/day of an optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, said optically pure (S,S) reboxetine being substantially free of (R,R) reboxetine.
Dependencies are inferred from the claim text.